We are proud to announce that our team of researchers has been selected to present a scientific poster at the prestigious 2024 ASCO (American Society of Clinical Oncology) Annual Meeting in Chicago, May 31-June 4, 2024. The poster, titled "Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping, Prognostic Classification, and Predicts Response to Antibody Drug Conjugates,"showcases our latest advancements in the field of breast cancer diagnostics and treatment.

 The research presented in this poster builds upon the findings recently published in the preprint server medRxiv, where our team demonstrated a novel approach that significantly enhances breast cancer molecular subtyping, prognostic classification, and the ability to predict patient response to antibody drug conjugate therapies.

 "We are thrilled to have the opportunity to share our groundbreaking research with the global oncology community at ASCO Cancer 2024," said Dr. Pavol Čekan, CEO of MultiplexDX. "This poster presentation represents a major milestone in our efforts to transform the way breast cancer is diagnosed and treated, ultimately improving patient outcomes." The presentation of this research at ASCO Cancer 2024 will provide a unique opportunity for our team to engage with key opinion leaders, clinicians, and researchers in the field of oncology, fostering valuable collaborations and accelerating the translation of our innovative technologies into clinical practice.

For more information about this research and our participation in 2024 ASCO Annual Meeting, please visit our website or contact us at info@multiplexdx.com.

You can find the abstract HERE https://ascopubs.org/doi/abs/10.1200/JCO.2024.42.16_suppl.3069

HAVE A LOOK AT OUR POSTER HERE ASCO 2024 poster.pdf